Literature DB >> 5824067

A simple model of a steady state differentiating cell system.

S I Rubinow.   

Abstract

A simple theoretical model is hypothesized to describe the steady state behavior of a differentiating cell system as exemplified by blood cells. The cell system consists of several morphologically distinguishable cell classes which develop sequentially. Each cell class except the last one is mitotically capable. Mitosis is assumed to be either heteromorphogenic, homomorphogenic, or asymmetric. Some algebraic equations are derived which are conservation equations describing the flux of cells from one class to another. The theoretical considerations have been applied to some experimental observations in humans concerning neutrophil production, particularly in reference to relative cell numbers and mitotic fractions of the myeloblast, promyelocyte, and myelocyte cell classes. These observations are utilized to help determine the values of the parameters which characterize the model. Among these parameters are the generation times of the various cell classes, and the predicted values of the generation times are found to be in excellent agreement with observed grain-count halving times. However, the predicted mitotic times are in disagreement with their observed values.

Entities:  

Mesh:

Year:  1969        PMID: 5824067      PMCID: PMC2107835          DOI: 10.1083/jcb.43.1.32

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  7 in total

1.  MITOTIC INDICES OF HUMAN BONE MARROW CELLS. 3. DURATION OF SOME PHASES OF ERYTHROCYTIC AND GRANULOCYTIC PROLIFERATION COMPUTED FROM MITOTIC INDICES.

Authors:  S A KILLMANN; E P CRONKITE; T M FLIEDNER; V P BOND
Journal:  Blood       Date:  1964-09       Impact factor: 22.113

2.  Mitotic indices of human bone marrow cells. I. Number and cytologic distribution of mitoses.

Authors:  S A KILLMANN; E P CRONKITE; T M FLIEDNER; V P BOND
Journal:  Blood       Date:  1962-06       Impact factor: 22.113

3.  Mitotic indices of human bone marrow cells. II. The use of mitotic indices for estimation of time parameters of proliferation in serially connected multiplicative cellular compartments.

Authors:  S A KILLMANN; E P CRONKITE; T M FLIEDNER; V P BOND; G BRECHER
Journal:  Blood       Date:  1963-02       Impact factor: 22.113

4.  A unifying concept of the etiology of the leukemias, lymphomas, and cancers.

Authors:  E E OSGOOD
Journal:  J Natl Cancer Inst       Date:  1957-02       Impact factor: 13.506

5.  Cell size distribution and single cell growth in Tetrahymena pyriformis GL.

Authors:  O SCHERBAUM; G RASCH
Journal:  Acta Pathol Microbiol Scand       Date:  1957

6.  Granulocytopoiesis in human bone marrow cultures studied by means of kinematography.

Authors:  I Boll; A Kühn
Journal:  Blood       Date:  1965-10       Impact factor: 22.113

7.  A maturity-time representation for cell populations.

Authors:  S I Rubinow
Journal:  Biophys J       Date:  1968-10       Impact factor: 4.033

  7 in total
  5 in total

Review 1.  Mechanistic models for myelosuppression.

Authors:  Lena E Friberg; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

2.  A mathematical model of neutrophil production and control in normal man.

Authors:  S I Rubinow; J L Lebowitz
Journal:  J Math Biol       Date:  2017-03-15       Impact factor: 2.259

3.  Optimization of combination therapy for chronic myeloid leukemia with dosing constraints.

Authors:  Helen Moore; Lewis Strauss; Urszula Ledzewicz
Journal:  J Math Biol       Date:  2018-07-10       Impact factor: 2.259

4.  Parameterization of in vivo leukemic cell populations.

Authors:  S I Rubinow; J L Lebowitz; A M Sapse
Journal:  Biophys J       Date:  1971-02       Impact factor: 4.033

5.  Comparison of Predator-Prey Model and Hawk-Dove Game for Modelling Leukemia.

Authors:  Mariam Sultana; Fareeha Sami Khan; M Khalid; Areej A Al-Moneef; Ali Hasan Ali; Omar Bazighifan
Journal:  Comput Intell Neurosci       Date:  2022-09-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.